AR and posterior cortical atrophy: Recently, the combination of ADT with docetaxel has also been introduced in the metastatic castrate-naive setting as this combination significantly increased overall survival.4,5 Conversely, docetaxel without ADT after radical prostatectomy did not delay disease recurrence.6 These clinical trials suggest that the antitumour efficacy of docetaxel in castrate-naive PCa (CNPC) is improved by inhibition of AR-pathway signalling.